US – The National Institute of Allergy and Infectious Diseases’ (NIAID) phase 1 clinical trials of its malaria vaccine, Sanaria (PfSPZ), have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. Trials were conducted at the National Institutes of Health (NIH) Clinical Centre in Bethesda, Maryland led by Patrick E. Duffy, M.D., of the NIH National Institute of Allergy and Infectious Diseases (NIAID), and Stephen L. Hoffman, M.D., CEO of Sanaria Inc., Rockville, Maryland. In the CVac trials, healthy…
Read MoreBreakthrough as phase 1 clinical malaria vaccine trial results come positive with proof to give strong lasting protection against malaria
